BiVictriX Therapeutics plc - Intention to float on AIM

BiVictriX Therapeutics plc, the developer of targeted cancer therapies based on its novel Bi-Cygni® approach, announces its intention to apply for admission to trading on AIM a market operated by the London Stock Exchange plc.

View PDF Announcement

View Admission Document

newsletter

Contact BivictriX

Please submit the form below and we shall be in touch
* We don't share your data. See our Privacy Policy
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.